According to filings with the U.S. Securities and Exchange Commission, Enlaza Therapeutics is raising up to $15,000,000.00 in new funding. The federal securities law requires the notice to be filed by companies that have sold securities without registration under the Securities Act of 1933 in an offering made under Rule 504 or 506 of Regulation D or Section 4(a)(5) of the Securities Act. A company must file this notice within 15 days after the first sale of securities in the offering. For this purpose, the date of first sale is the date on which the first investor is irrevocably contractually committed to invest. Each issuer of securities that sells its securities in reliance on an exemption provided in Regulation D or Section 4(a)(5) of the Securities Act of 1933 must file this notice containing the information requested with the U.S. Securities and Exchange Commission (SEC) and with the state(s) requiring it. If more than one issuer has sold its securities in the same transaction, all issuers should be identified in this filing with the SEC.

About Enlaza Therapeutics
Enlaza Therapeutics is pioneering the field of covalent biologics. These novel classes of protein therapeutics deliver more efficacious and safer treatments for patients. The companys proprietary War-Lock platform leverages leading synthetic biology technology for site-specific covalent coupling driven by drug binding. Enlaza is building a pipeline of first-in-class covalent biologics..

To learn more about Enlaza Therapeutics, visit https://enlazatx.com/
Enlaza Therapeutics Linkedin Page: https://www.linkedin.com/company/enlaza-therapeutics/

Contact:
Sergio Duron, Chief Executive Officer
858-348-2180
https://www.linkedin.com/in/sergio-duron-6256818/

SOURCE: http://www.intelligence360.io
Copyright (c) 2025 SI360 Inc. All rights reserved.